hERG (the human Ether-à-go-go-Related Gene)，是指基因KCNH2。该基因编码的蛋白质被称为 K_v11.1，是钾离子信道(英语：potassium ion channel)的α亚基（英语：alpha subunit）。该基因编码的钾离子信道（有时简单地使用'hERG'表示）最为著名的是其对心脏的电位活性，可协调心跳（即，hERG信道介导在心脏动作电位中延迟整流钾电流--I_Kr的复极化）。当这个信道介导电流通过细胞膜的能力受到抑制或妥协让步时，不论是由于药物的作用还是某些家族的基因突变引发，，都会导致潜在的致命疾病——QT间期延长综合症。若干临床上成功的上市药物有抑制hERG的趋势，导致其在使用过程中也伴随着猝死的药物不良反应风险。因此，在药物研发过程中要尽量避免药物对抗靶标(英语：antitarget)的hERG抑制。 hERG还跟神经系统的某些细胞功能的调节 以及白血病细胞癌症特性的创建和维持有关。

hERG (the human Ether-à-go-go-Related Gene) is a gene (KCNH2) that codes for a protein known as K_v11.1, the alpha subunit of a potassium ion channel. This ion channel (sometimes simply denoted as 'hERG') is best known for its contribution to the electrical activity of the heart that coordinates the heart's beating (i.e., the hERG channel mediates the repolarizing I_Kr current in the cardiac action potential). When this channel's ability to conduct electrical current across the cell membrane is inhibited or compromised, either by application of drugs or by rare mutations in some families, it can result in a potentially fatal disorder called long QT syndrome; a number of clinically successful drugs in the market have had the tendency to inhibit hERG, and create a concomitant risk of sudden death, as a side-effect, which has made hERG inhibition an important antitarget that must be avoided during drug development. hERG has also been associated with modulating the functions of some cells of the nervous system and with establishing and maintaining cancer-like features in leukemic cells.